Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in chronic heart failure with reduced ejection fraction
ChiCTR2100052426Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xinjiang Medical University
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure (HF) comparing Dapagliflozin group with Placebo group (2 arms). Primary endpoints: Heart rate variability and Ventricular arrhythmias. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2100052426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052426.